Akorn takes Manivest to 38,70 return to date

Akork has been our single largest position for the last 6 months with bad performance until last week. We had an idea, that the company was undervalued and also that they would be a very attractive take-over candidate for some of the larger health-care companies, as they now have incorporated their acquisitions and become a significant larger player in the market. Friday it was revealed that German Fresenius SE is in talks with Akorn about a possible take-over leading the stock upwards 18% plus another 13 in after-market trading. This boosted overall Manivest performance this year to a staggering 38,70%. More info will follow next week.

PLEASE READ OUR DISCLAIMER http://manivest.net/manivest-disclaimer